Biology Reference
In-Depth Information
Amsallem E, Kasparian C, Haddour G, Boissel JP, Nony P (2005) Phosphodiesterase III inhibitors
for heart failure. Cochrane Database Syst Rev CD002230
Amsterdam A, Sasson R (2002) The anti-inflammatory action of glucocorticoids is mediated by
cell type specific regulation of apoptosis. Mol Cell Endocrinol 189:1-9
Aoki M, Fukunaga M, Sugimoto T, Hirano Y, Kobayashi M, Honda K, Yamada T (2001) Studies
on mechanisms of low emetogenicity of YM976, a novel phosphodiesterase type 4 inhibitor.
J Pharmacol Exp Ther 298:1142-1149
Aoshiba K, Nagai A (2004) Differences in airway remodeling between asthma and chronic
obstructive pulmonary disease. Clin Rev Allergy Immunol 27:35-44
Banner KH, Press NJ (2009) Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive
pulmonary disease. Br J Pharmacol 157:892-906
Bardin PG, Dorward MA, Lampe FC, Franke B, Holgate ST (1998) Effect of selective
phosphodiesterase 3 inhibition on the early and late asthmatic responses to inhaled allergen.
Br J Clin Pharmacol 45:387-391
Barnes PJ (2003) Theophylline: new perspectives for an old drug. Am J Respir Crit Care Med
167:813-818
Barnes PJ (2006) How corticosteroids control inflammation. Br J Pharmacol 148:245-254
Beck CA, Weigel NL, Edwards DP (1992) Effects of hormone and cellular modulators of protein
phosphorylation on transcriptional activity, DNA binding, and phosphorylation of human
progesterone receptors. Mol Endocrinol 6:607-620
Benayoun L, Druilhe A, Dombret MC, Aubier M, Pretolani M (2003) Airway structural alterations
selectively associated to severe asthma. Am J Respir Crit Care Med 167:1360-1368
Bender AT, Beavo JA (2006) Cyclic nucleotide phosphodiesterases: molecular regulation to
clinical use. Pharmacol Rev 58:488-520
Bentley JK, Kadlecek A, Sherbert CH, Seger D, Sonnenburg WK, Charbonneau H, Novack JP,
Beavo JA (1992) Molecular cloning of cDNA encoding a “63”-kDa calmodulin-stimulated
phosphodiesterase from bovine brain. J Biol Chem 267:18676-18682
Bharani A, Mathew V, Sahu A, Lunia B (2003) The efficacy and tolerability of sildenafil in
patients with moderate-to-severe pulmonary hypertension. Indian Heart J 55:55-59
Blease K, Burke-Gaffney A, Hellewell PG (1998) Modulation of cell adhesion molecule
expression and function on human lung microvascular endothelial cells by inhibition of
phosphodiesterases 3 and 4. Br J Pharmacol 124:229-237
Bodor N (1984) Soft drugs: principles and methods for the design of safe drugs. Med Res Rev
4:449-469
Boswell-Smith V, Spina D, Oxford AW, Comer MB, Seeds EA, Page CP (2006) The pharmacol-
ogy of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9, 10-dimethoxy-2
(2, 4, 6-trimethyl- phenylimino)-3-(N-carbamoyl-2-aminoethyl)-3, 4, 6, 7-tetrahydro-
2H-pyrimido[6, 1-a] isoquinolin-4-one] and RPL565 [6, 7-dihydro-2-(2, 6-diisopropylphenoxy)-
9, 10-dimethoxy-4H-pyrimido[6, 1-a]isoquino lin-4-one]. J Pharmacol Exp Ther 318:840-848
Brunnee T, Engelstatter R, Steinijans VW, Kunkel G (1992) Bronchodilatory effect of inhaled
zardaverine, a phosphodiesterase III and IV inhibitor, in patients with asthma. Eur Respir
J 5:982-985
Bruss MD, Richter W, Horner K, Jin SL, Conti M (2008) Critical role of PDE4D in
b
2
-adrenoceptor-
dependent cAMP signaling in mouse embryonic fibroblasts. J Biol Chem 283:22430-22442
Bureau Y, Handa M, Zhu Y, Laliberte F, Moore CS, Liu S, Huang Z, MacDonald D, Xu DG,
Robertson GS (2006) Neuroanatomical and pharmacological assessment of
Fos
expression
induced in the rat brain by the phosphodiesterase-4 inhibitor, 6-(4-pyridylmethyl)-8-(3-nitro-
phenyl) quinoline. Neuropharmacology 51:974-985
Burgin AB, Magnusson OT, Singh J, Witte P, Staker BL, Bjornsson JM, Thorsteinsdottir M,
Hrafnsdottir S, Hagen T, Kiselyov AS, Stewart LJ, Gurney ME (2010) Design of phosphodi-
esterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety.
Nat Biotechnol 28:63-70
Burnouf C, Pruniaux MP (2002) Recent advances in PDE4 inhibitors as immunoregulators and
anti-inflammatory drugs. Curr Pharm Des 8:1255-1296
